Greenberg Traurig LLP

Litigation

Shareholder

Brian Rubenstein has a broad range of experience defending pharmaceutical and other companies in a range of large-scale, complex matters. Prior to joining Greenberg Traurig, Brian was with Teva Pharmaceuticals, USA, Inc. from 2005 to 2018, where he most recently served as Senior Director, Associate General Counsel. At Teva, he managed and exercised direct oversight of Teva’s portfolio of product liability, patent settlement antitrust, and other commercial matters, managing a multimillion-dollar annual legal budget.

Brian guided and counseled Teva through all stages of litigation and dispute resolution, both in federal court and in numerous state court jurisdictions. Most prominently, he managed Teva’s involvement in the landmark U.S. Supreme Court case, Pliva v. Mensing, in which the majority found that “failure to warn” product liability lawsuits against generic pharmaceutical manufacturers are preempted by federal law, a sea change in the law concerning generic pre-emption. He also counseled Teva on antitrust issues, in particular “pay to delay” matters, as well as on labeling and related regulatory issues. In addition, he provided counseling to various business units to ensure compliance with the existing regulatory regime, as well as created and implemented strategies to adapt to potential rule changes for generic pharmaceutical products.

ConcentrationsProducts liabilityFDA compliance and inquiry responsesFTC compliance and inquiry responsesMultidistrict and mass tort litigationAntitrust

CapabilitiesLitigation Pharmaceutical, Medical Device & Health Care LitigationProducts Liability & Mass Torts

Admission to PracticePennsylvaniaNew York

English

J.D., cum laude, Loyola University Chicago School of Law, 1998 Member, Loyola University Chicago Law Journal B.S., Wharton School of Business, University of Pennsylvania, 1995